GWS
FATE icon

Glassman Wealth Services’s Fate Therapeutics FATE Stock Holding History

Glassman Wealth Services’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53
Closed -$112 – 2010
2023
Q3 		$112 Buy
+53
New +$176 ﹤0.01% 1961
2023
Q1 		– Sell
-76
Closed -$767 – 1925
2022
Q4 		$767 Buy
76
+71
+1,420% +$1.33K ﹤0.01% 1505
2022
Q3 		$0 Sell
5
-7
-58% -$202 ﹤0.01% 1757
2022
Q2 		$0 Buy
+12
New +$331 ﹤0.01% 1770
2021
Q4 		– Sell
-33
Closed -$2K – 1713
2021
Q3 		$2K Buy
33
+30
+1,000% +$2.35K ﹤0.01% 1162
2021
Q2 		$0 Buy
3
+2
+200% +$161 ﹤0.01% 1510
2021
Q1 		$0 Buy
+1
New +$96 ﹤0.01% 1466
2019
Q3 		– Sell
-11
Closed – – 1137
2019
Q2 		$0 Buy
+11
New +$198 ﹤0.01% 1160

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Glassman Wealth Services's FATE Position: Q4 2023 in Review

Glassman Wealth Services sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 53 shares — an estimated $112 sold.

Glassman Wealth Services first reported a position in FATE in Q2 2019 and held it in 8 quarters. The position peaked at $2K in Q3 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Glassman Wealth Services reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 53 Fate Therapeutics shares in Q4 2023, an estimated $112.
  • Glassman Wealth Services first reported a position in Fate Therapeutics in Q2 2019 and held it in 8 quarters.
  • Glassman Wealth Services's Fate Therapeutics position peaked at $2K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Glassman Wealth Services's 13F filing for Q4 2023, filed 12 Feb 2024.